Clinical trial
A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers.
NCT03926819 is registered in ClinicalTrials.gov with Hillhurst Biopharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open Labeled Single Ascending Dose Followed by Multiple Dose Safety and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Healthy Adult Volunteers.
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 25, 2022
- Completion date
- April 26, 2023
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.